Kornimate/medical-research-clean huggingface dataset:
tumor associated macrophage in advanced non-small cell lung cancer

Conditions: Advanced Nonsmall Cell Lung Cancer

Summary: the purpose of this study is to investigate the effects of tumor associated macrophage (tam) in advanced non-small cell lung cancer (nsclc) patients on the treatment response and outcome of these subjects. pathologic specimens from tissue bank will be stained by immunostaining methods with cd68 antibody. the clinical treatment response and outcomes will be analyzed between high or low tam.


Eligibility criteria:
inclusion criteria: * advanced nsclc, * more than 20 years old, * measurable tumor, * response and outcome recorded after the first line treatment. exclusion criteria: * early stage nsclc, * less than 20 years, * pregnancy, * unmeasurable nsclc.
safety and efficacy of nyxol with pilocarpine eye drops in subjects with presbyopia

Conditions: Presbyopia

Summary: the objectives of this study are: to evaluate the efficacy of nyxol + pilocarpine to improve dcnva in subjects with presbyopia


Eligibility criteria:
inclusion criteria: 1. males or females ≥ 40 and ≤ 64years of age. 2. bcdva of 0.0 logmar(20/20 snellen equivalent) or better in each eye under photopic conditions. 3. dcnva of 0.4 logmar (20/50 snellen equivalent) or worse under photopic conditions in each eye and binocularly. 4. subjects who depend on reading glasses or bifocals in which their binocular best-corrected near va is 0.1 logmar (20/25 snellen equivalent) or better. exclusion criteria: ophthalmic (in either eye): 1. use of any topical prescription or otc ophthalmic medications of any kind within 7 days of screening until study completion. 2. use of any over-the-counter (otc) artificial tears (preserved or unpreserved) at least once per day within 7 days of screening until study completion. 3. current use of any topical ophthalmic therapy for dry eye. 4. tear break-up time of \< 5 seconds or corneal fluorescein staining. 5. clinically significant ocular disease that might interfere with the study as deemed by the investigator. 6. recent or current evidence of ocular infection or inflammation in either eye. 7. any history of herpes simplex or herpes zoster keratitis. 8. history of diabetic retinopathy or diabetic macular edema. 9. known allergy, hypersensitivity, or contraindication to any component of the phentolamine, pilocarpine, or vehicle formulations. 10. history of cauterization of the punctum or punctal plug (silicone or collagen) insertion or removal. 11. ocular trauma, ocular surgery, ocular laser treatment within the 6 months prior to screening. any subject with multifocal intraocular lenses are excluded. 12. history of any traumatic (surgical or nonsurgical) or non traumatic condition affecting the pupil or iris. 13. unwilling or unable to discontinue use of contact lenses. 14. conjunctival hyperemia ≥ grade 2 on the cclru 4-point scale. systemic: 15. known hypersensitivity or contraindication to alpha- and/or beta adrenoceptor antagonists. 16. known hypersensitivity or contraindication to any systemic cholinergic parasympathomimetic agents. 17. clinically significant systemic disease that might interfere with the study as deemed by the investigator. 18. participation in any investigational study within 30 days prior to screening. 19. females of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. 20. resting hr outside the specified range of 50 to 110 beats per minute. 21. hypertension with resting diastolic bp \> 105 mmhg or systolic bp \> 160 mmhg.

Keywords: nyxol presbyopia pilocarpine
sdm laser for non central diabetic csme

Conditions: Non Central Diabetic Macular Edema

Summary: is to determine if sdm laser can reduce macular thickness in non central csme and stop the progression of non central csme to central csme in compare to glycemic control

interventional randomised masked study will recruit patients have diabetes mellitus with non central csme with good vision into two groups : 1st sdm laser with glycemic control 2nd sham laser with glycemic control where bcva will be recorded every month starting from baseline to 24 weeks where oct will be recorded every 8 weeks from baseline to 24 weeks

Eligibility criteria:
inclusion criteria: * patients with central diabetic macular edema best corrected visual acuity is 20/30 or more * non central macular thickness more than 250 microns * patients who are able to come for all follow-up exclusion criteria: * significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant. * myocardial infarction, other acute cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 4 months prior to randomization * for women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 3 years. * macular edema is present that is considered to be related to ocular surgery such as cataract extraction * substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by 3 lines or more * history of major ocular surgery (including vitrectomy, scleral buckle, any intraocular surgery, etc.) within prior 4 months or anticipated within the next 6 months following randomization. * exam evidence of severe external ocular infection, including conjunctivitis, chalazion, or substantial blepharitis
survivorship study of cancer patients who received cranial radiation therapy

Conditions: Brain Metastases, Adult; Primary Brain Tumor; Lung Cancer

Summary: this study represents a survivorship protocol that focuses on cognition and health-related quality of life (hrqol) in cancer patients that have received prior brain irradiation. the primary purpose of this study is to assess the feasibility of using a digital symptom tracking application focused on hrqol and cognition in cancer survivors who received brain irradiation.

patients who may participate in the study are cancer survivors who received cranial irradiation for conditions including, but not limited to: primary brain tumors, brain metastases, patients with lung cancer receiving prophylactic brain irradiation, and long-term survivors of pediatric cancers. patients will use the noona® healthcare mobile pro application to identify real time select hrqol and cognitive symptoms. patients will be instructed to log symptoms as often as relevant using their own personal devices, as well as be prompted to fill out the patient-reported outcomes measurement information system global health screen (promis global health-10 and edmonton symptom assessment scale) during treatment (weeks 9 and 14). patient engagement with the application will be tracked to determine feasibility.

Eligibility criteria:
inclusion criteria: 1. cancer survivors who received cranial irradiation including, but not limited to, primary brain tumor, brain metastases, lung cancer receiving prophylactic brain irradiation, long-term survivors of pediatric cancers 2. initial radiation must have been completed more than 6 months prior to enrollment. acceptable radiation therapies include fractionated partial brain irradiation, whole brain irradiation, or stereotactic radiosurgery (for any modality at least a total cumulative dose of 20 gy) of at least 20 gy 3. age ≥ 18 years at the time of entry into the study 4. karnofsky performance score (kps) ≥ 70 or eastern cooperative oncology group (ecog) grade ≤ 2 5. no imaging evidence of disease progression within 4 months of enrollment 6. life expectancy \> 6 months per treating neuro-oncology providers 7. access to a smartphone, tablet, or computer with capability to utilize the mobile symptom-tracking application 8. subject must be fluent in english exclusion criteria: 1. active psychiatric illness

Keywords: pro00102684 katherine peters lung cancer brain metastases brain tumor radiation solid tumor cognition pediatric cancer cancer survivor survivorship noona healthcare mobile application
a study to evaluate and compare injections of autologous mixed population of dermal cells into the balding scalp of subjects with hair loss (ca-0004542)

Conditions: Androgenetic Alopecia; Male Pattern Baldness; Female Pattern Baldness

Summary: the purpose of the the study is to evaluate the ability of injections of ji gami(tm) c to induce hair growth in male and female subjects with hair loss.


Eligibility criteria:
inclusion criteria: * male and female volunteers 18 to 65 years old, inclusive * hair loss consistent with ≥ grade iii-vertex, iv, va, v, and vi, based on norwood-hamilton scale providing there is bridging of hair in the anterior edge of the vertex circle. * able to provide informed consent after risks and benefits of the study have been explained. * be willing to undergo all study procedures. * ability to communicate effectively with study personnel. * have no clinically significant disease or abnormal laboratory evaluations taken at the screening visit. * agree to abstain from use of any hair growth affecting oral or topical medication including over the counter and herbal medications, minoxidil, finasteride or dutasteride during the course of this study. exclusion criteria: * known sensitivity to dmem/f-12 or any component of the study material. * known hypersensitivity to clindamycin hydrochloride, amphotericin b or streptomycin sulfate. * subjects who have used minoxidil or any oral or topical medication including over the counter and herbal medications for the treatment of hair loss within 6 months of study screening, or finasteride or dutasteride within 12 months of study screening. * a history of drug or alcohol abuse within 1 year of study enrollment. * paricipation in any other investigational study within 30 days or six half lives of its biologic activity, whichever is longer, before the scalp excision visit(s), and during the time enrolled in this study. * clinically significant medical or psychiatric illness currently or within 30 days of study screening as determined by the investigator. * clinically significant abnormal laboratory parameters. * a positive result at screening for human immunodeficiency virus (hiv 1 or 2), hepatitis b or c, htlv i/ii. * clinically significant dermatologic condition in donation or study areas. * prior surgery in the donor or study areas. * insufficient hair or scarring in the donor area that might impact cell growth. * any disease or condition (medical or surgical) that, in the opinion of the investigator, might compromise hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system function; or any condition that would place the subject at increased risk.

Keywords: androgenetic alopecia male pattern baldness female pattern baldness hair loss baldness
ctc pancreatic adenocarcinoma

Conditions: Adenocarcinoma; Circulating Tumor Cells; Pancreatic Neoplasms

Summary: proportion of circulating tumor cells (ctc) in the postoperative phase after curative tumor removal of pancreatic cancer will be determined and correlated to the accordance of anesthesia (desflurane versus propofol)

this prospective, randomized study will be conducted over a 36-month period to investigate whether commonly used anesthetics (volatile versus intravenous) have an effect on the changes or occurrence of ctc in patients suffering from primary pancreatic cancer undergoing curative surgery. the specific research question is if there are changes of the ctc count in the postoperative phase in the desflurane group (intervention) compared to the propofol one (control). a secondary question is if these changes can be correlated to tumor outcome.

Eligibility criteria:
inclusion criteria: * age 18 to 85 * asa i-iii ( american society of anesthesiologists) * resectable pancreatic adenocarcinoma * primary surgery * no neoadjuvant therapy * written informed consent exclusion criteria: * metastatic disease * other than primary surgery (recurrence, reconstruction) * pre-operative chemotherapy * chronic opioid use * known hypersensitivity or suspected allergy to propofol, soya or egg proteins * known hypersensitivity to volatile anaesthetics (malignant hyperthermia) * pregnancy * breast feeding * enrolment in any other clinical trial during the course of this trial, 30 days prior to its beginning or 30 days after its completion

Keywords: circulating tumor cells anesthesia and immunity cell search system
ability of near infrared spectroscopy to isolate compartments of the extremity

Conditions: Acute Compartment Syndrome

Summary: near infrared spectroscopy (nirs) provides a non-invasive means of continuously monitoring tissue oxygenation, which may be useful for diagnosis of acute compartment syndrome (acs). placement of these sensor pads on the surface of the skin must be such that light penetrates the intended compartment without inadvertently obtaining measurements of an adjacent compartment. the objective of this study is to examine whether the nirs measurements of each compartment truly represent the tissue perfusion of the intended compartment, as indicated by the predictable decrease in muscle oxygenation of a given compartment in response to muscle fatigue. the investigators hypothesize that the tissue oxygenation values of the stimulated compartment will significantly decrease following muscle stimulation, indicating that the intended muscle compartment was successfully isolated. additionally, the investigators hypothesize that nirs values of unstimulated muscle compartments will not change from baseline.


Eligibility criteria:
inclusion criteria: * 18-75 years old * no current extremity injuries * willing to provide written informed consent exclusion criteria: * history of any anatomy-altering surgery to the extremity in question * history of peripheral vascular disease * history of pulmonary disease

Keywords: near-infrared spectroscopy
nutritional parameters and other risk factors affecting severity of pneumonia in children under five years in upper egypt

Conditions: Hypoalbuminemia; Stunted Growth; Anemia, Iron Deficiency

Summary: decrease mortality rate resulting from pneumonia

recruiting patients with pneumonia admitted at assiut university hospital . then assessment of their condition and severity of pneumonia by examination and x-ray chest . after that, we aim at assessment their nutrition status and it's effect on severity of pneumonia. so we aim to investigate them by cbc, albumin, crp and cxr and correlate these parameters with the severity of pneumonia to assess the impact of nutrition on outcome of chest infections

Eligibility criteria:
inclusion criteria: * diagnosis of pneumonia on day 1 of hospital admission. exclusion criteria: * patients with cardiac diseases * patients with immune deficiency disorders

Keywords: pneumonia, nutrition, blood tests, body mass index
greening the humanitas fertility center: how to build a more sustainable medical daily routine

Conditions: Sustainability; Female Infertility

Summary: the goal of this observational study is to redefine an everyday clinical routine at the humanitas fertility center calculating the effects derived from the reduction of inappropriate and avoidable tests, procedures, tools and treatments currently used. anonymized patients data about clinical procedures are used, taken from the internal database of the humanitas fertility center


Eligibility criteria:
all outpatient, surgical and laboratory procedures, considered as daily clinical routine at the humanitas fertility center, will be taken into account, analysed and defined as appropriate or not.
sublingual sufentanil pca usability for postoperative pain (zalviso® system)

Conditions: Trauma; Surgery

Summary: intravenous patient-controlled analgesia (iv-pca) is the gold standard for the treatment of moderate to severe postoperative pain. it is used in more than 20% of cases after major surgery. well known disadvantages of this method include the need of intravenous line (invasive, infection risk), the risk of pump programming error, possible delay for ambulation/barrier for enhanced rehabilitation programmes, and time/resource demanding (the need of preparation and installation). sublingual sufentanil based pca (zalviso®) addresses cited issues. the safety and analgesia efficiency of this system is well described. however, the usability and satisfaction of zalviso® varies depending on clinical settings. the goal of this study is to evaluate the usability and satisfaction of patients, nurses, and physical therapists using zalviso® system during the first 72 hours in the settings of enhanced recovery after surgery protocol after major interventions associated with moderate to severe postoperative pain.


Eligibility criteria:
inclusion criteria: * adults * 16 \<bmi \<40 * asa i and ii * patient with traumatic functional surgery - knee and hip arthroplasty, shoulder surgery, tibial osteotomy / femoral osteotomy; or plastic and aesthetic surgery with volume correction of more than 30% of body surface area (bodylift), diep, dla. * patient who should theoretically benefit of a postop self-controlled analgesia of morphine for 72 hours on average * patient informed of the modalities of the study with delivery of an information leaflet * free and informed consent collection exclusion criteria: * patient refusing to participate in the study * language barrier * hypersensitivity to sufentanil, * respiratory failure * renal insufficiency (gfr \<30 ml / min) * epilepsy not controlled by treatment * psychic and mental illness not controlled by treatment * hepatocellular insufficiency (tp \<50%) * heart failure (lvef \<50%) * patients with chronic pain, treated with level 3 analgesic and / or already treated for neuropathic pain * drug-addicted patients * pregnant or lactating women
a study for schizophrenia relapse prediction

Conditions: Schizophrenia

Summary: the purpose of this study is to identify if there are self-reported/caregiver reported or objective measures that can predict near-term relapse (within 1 month or at another identified time point before meeting the criteria for relapse) or early symptomatic changes indicative of pre-relapse.


Eligibility criteria:
inclusion criteria: * participants and their legally acceptable representative where applicable must be able to sign an informed consent form (icf) indicating that he or she understands the purpose of and procedures required for the study and is willing to participate for the duration of the study * have a clinical diagnosis of schizophrenia made by a clinician with understanding of the criteria for schizophrenia or schizoaffective disorder, per the diagnostic and statistical manual of mental disorders - 5th edition (dsm-5), and had at least 1 relapse, in the opinion of the investigator, within the last 12 months prior to date of informed consent * must be receiving an oap treatment regimen at the time of enrollment * must be able to speak, read, and understand english and/or the local indian language as the patient reported outcome instruments will be validated in regional languages * caregivers/informants should be able to sign an icf indicating that he or she understands the purpose of and procedures required for the study and is willing to participate for the duration of the study exclusion criteria: * has treatment resistant schizophrenia (that is, currently receiving clozapine or electroconvulsive therapy \[ect\]) * is on long-acting injectable antipsychotic regimen at the time of screening * has a moderate to severe substance use disorder (other than nicotine), as determined by the investigator * has a significant risk of suicide or active suicidality with a plan as indicated by the columbia-suicide severity rating scale (c-ssrs) assessment * has an immediate need for hospitalization (that is, the participant is already in a relapse)
frequency and clinical significance of renal and bone toxicity in hiv-infected patients

Conditions: Renal Toxicity

Summary: the purpose of this study is to determine the frequency of renal and bone toxicity in hiv infected patients receiving antiretroviral therapy, and the outcome in terms of treatment change or/and virological failure, in relation with the presence of classical factors, such as diabetes or hypertension, the role of hiv itself, because of chronic inflammation, and the effects of antiretroviral medication.

this is a retrospective cohort study involving 300 patients to determine the frequency of renal and bone comorbidities/toxicity in a large population of hiv-infected patients receiving antiretroviral therapy, in order to establish the differential role of classical factors, hiv infection, or antiretroviral therapy.

Eligibility criteria:
inclusion criteria: * confirmed hiv infection exclusion criteria: * pregnancy * prior therapy with antineoplastic chemotherapy or chronic treatment with corticosteroids * previous chronic therapy with antiresorptive bone therapy

Keywords: hiv, antiretroviral, toxicity, egfr, tubular disease, bmd
meperidine versus drotaverine regarding the effect on the duration of the first stage of labor in full term primigravidae

Conditions: Effect of Meperidine or Drotaverine on Effacement and Dilatation of the Cervix During Labor in Full Term Primigravidae

Summary: comparison between meperidine and drotaverine regarding the effect on the duration of the first stage of labor in full term primigravidae

comparison between meperidine and drotaverine regarding the effect on the duration of the first stage of labor in full term primigravidae protocol of thesis submitted for partial fulfillment of master degree in obstetrics \& gynecology the aim of this work is to compare and to evaluate the efficacy of drotaverine hydrochloride versus meperidine hydrochloride on the duration of the 1st stage of labor.

Eligibility criteria:
inclusion criteria: ● primigravida. * singleton pregnancy. * term gestation i.e, 38-41 weeks. * sure, reliable dates documented by ultrasound in the 1st half of pregnancy. * vertex presentation with occipito anterior position. * efficient uterine contractions at a rate of at least 3 to 4 contractions every 10 minutes, each contraction lasting for at least 40 seconds. exclusion criteria: ● abnormal presentation or occipito posterior position. * multiple pregnancies. * cephalo-pelvic disproportion. * cervical surgery in the past or history of cervical injury. * patients on antihypertensive therapy. * known hypersensitivity to drotaverine or meperidine. * if any other spasmolytic agent had been used within 48 hours.